Proteostasis Therapeutics has started with the phase 2 study of cystic fibrosis treatment by dosing the first patient, after a successful Phase 1 test of PTI’s combinations.
“Despite the inclusion of CF subjects colonized with bacteria associated with a more rapid decline in lung function, our doublet and triplet studies have delivered a compelling signal of ppFEV1 improvement,” said Geoffrey Gilmartin, Chief Medical Officer of Proteostasis. “By focusing on European centers, our next stage in development will target the recruitment of patients comparable to those used in other CFTR modulator combination studies which, together with optimal dose levels and longer treatment duration, could potentially further enhance the magnitude of pulmonary benefit.”